IMR Press / FBE / Volume 5 / Issue 1 / DOI: 10.2741/E592

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Advances in management of uterine myomas

Show Less
1 Department of Obstetrics and Gynecology, Pt. B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India

*Author to whom correspondence should be addressed.

Academic Editor: Indrajit Chowdhury

Front. Biosci. (Elite Ed) 2013, 5(1), 12–22; https://doi.org/10.2741/E592
Published: 1 January 2013
(This article belongs to the Special Issue Recent progress in reproductive biology)
Abstract

Uterine myomas, the most common benign solid pelvic tumors in women, occur in twenty percent of them in reproductive years and form the most common indication for hysterectomy. Various factors affect the choice of the best treatment modality for a given patient. Asymptomatic myomas may be managed by careful follow up. Medical therapy should be tried as a first line of treatment for symptomatic myomas while surgical treatment should be reserved only for appropriate indications. Myomectomy would be preferred over hysterectomy in those wishing subsequent childbearing. Preoperative GnRH- analogue treatment reduces the myoma size and vascularity but may render the capsule more difficult to resect. Poor surgical risk women with large symptomatic myomas or those wishing to avoid major surgical procedures may be offered uterine artery embolization. Serial follow-up for growth and symptoms may be appropriate for asymptomatic perimenopausal women. The present article reviews the available therapeutic modalities for uterine myomas.

Keywords
Uterine myomas
Treatment
Update
Review
Share
Back to top